LL-37 vs BPC-157
Side-by-side comparison of LL-37, BPC-157 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | LL-37 LL-37 (Human Cathelicidin Antimicrobial Peptide) Recovery | BPC-157 Body Protection Compound-157 Recovery |
|---|---|---|
| Basics | ||
| Molecular type | Human Cathelicidin | Gastric Pentadecapeptide |
| Amino acids | 37 | 15 |
| Molecular weight | 4,493.3 Da | 1,419.5 Da |
| Half-life | Short (hours) | ~4 hrs (SC) |
| Route(s) | Subcutaneous, Topical, Intranasal | Subcutaneous, Intramuscular, Oral (research only) |
| Mechanism & Research | ||
| Primary mechanism | LL-37 disrupts microbial membranes through electrostatic interaction — its cationic amphipathic helical structure inserts into negatively charged bacterial membranes, causing lethal membrane permeabilisation. This mechan… | BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery o… |
| Research status | Research Compound | Research Compound |
| Evidence summary | LL-37 has been studied extensively for wound healing, respiratory infections (including COVID-19 lung immunity), and more recently for senolytic applications. Its broad antimicrobial and immunomodulatory profile makes it… | The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and e… |
| Protocol & Dosing | ||
| Typical dose | 1–5 mg per injection or topical application | 200–500 mcg per injection |
| Frequency | Daily | Once or twice daily |
| Duration | 4–8 weeks | 4–12 weeks |
| Timing | Any time | Near injury site when possible |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Prohibited (WADA S0) |
| Deeper reading | ||
| Related peptides | BPC-157, GHK-Cu, KPV | TB-500, GHK-Cu, KPV, Pentadeca Arginate |
| Full profile | Read full LL-37 profile → | Read full BPC-157 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.